Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-142

@Pledge

Sorry to take so long to come back to you on your questions regarding inventories and bioreactors. I am sure you appreciate the Master Cell Bank stocks are normally held at cost or net realisable value (whichever is lower).
The reason I know that there is approx three years supply of Ryoncil already validated and available for use in paediatric sr aGVHD , is that the Company made reference to the fact when it took the stock write down in the accounts after the last CRL. I should note that most analysts forget this completely when building financial models and assume low gross margins on initial production, which would be the complete opposite in the event Ryoncil gets the nod. Note the seeking alpha hatchet piece appears to makes the same mistake, which is perfectly understandable when you hardly know the stock . OP










Please do not rely on the facts or opinions expressed in this post when making an investment decision.